Cancer Therapeutics CRC Enters Collaboration with Duke University to develop drugs for the treatment of cancer

06-Oct-2009 - USA

Cancer Therapeutics CRC Pty Ltd announced a collaboration with Duke University to discover and develop new drugs for the treatment of many forms of cancer, based on research undertaken by the laboratory of Duke Professor Patrick Casey.

Professor Casey and his team at Duke have been investigating lipid signaling pathways and the role of lipid metabolising enzymes in cancer for many years and have developed a series of promising new inhibitors of these enzymes. CTx has taken an exclusive license to these inhibitors and will initiate a drug development program to bring these early stage compounds toward the clinic.

CTx’s CEO, Tony Evans commented that collaborating with an academic medical center of Duke’s caliber is a major expansion of CTx’s capabilities in partnering with overseas cancer researchers in order to source the most promising novel targets for CTx’s drug discovery projects.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances